Literature DB >> 10785598

Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed.

G J Peters1, B van Triest, H H Backus, C M Kuiper, C L van der Wilt, H M Pinedo.   

Abstract

Inhibition of the key enzyme in DNA synthesis, thymidylate synthase (TS), by 5-fluorouracil (5-FU) and the novel antifolate raltitrexed (Tomudex; ZD1694), induces dTTP depletion, resulting in DNA strand breaks, which can initiate pathways leading to an apoptotic mode of cell death. We studied 5-FU- and ZD1694-induced TS inhibition in relation to the expression of p53, p21, Bcl-2 and Bax in six colon carcinoma cell lines, two with a wild-type (wt) p53 (Lovo, LS174T) and four with a mutant (mt) p53 (WiDr, WiDr/F, HT29 and SW948) phenotype. In untreated cells, a reciprocal correlation between p53 and Bcl-2 was found: in cells with a low wt p53, Bcl-2 expression was present; whilst in cells with mt p53, Bcl-2 expression was not detectable. Exposure to 5-FU (50 and 100 microM) and ZD1694 (50 and 100 nM) for 24 and 48 h induced p53 and p21 expression in wt p53 cells, but not in mt p53 cells. TS was induced approximately 2-10-fold in all cell lines. TS induction was highest after ZD1694 exposure in the mt p53 cells HT29 and WiDr/F (6-10-fold). After 5-FU treatment, TS was present both as the free enzyme and in the ternary complex; however, predominantly as the ternary complex between TS, FdUMP and 5,10-methylenetetrahydrofolate. In wt p53 cells, both drugs increased Bax expression up to 5-fold, whereas in mt p53 cells, only a very slight induction was found. In wt p53 cells, Bcl-2 expression hardly changed after drug treatment. These results indicate a p53-independent induction of TS but a regulatory role of wt p53 in the synthesis of Bax in the colon carcinoma cell lines after TS inhibition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10785598     DOI: 10.1016/s0959-8049(00)00026-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  20 in total

1.  Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines.

Authors:  Stefania Giudice; Luisa Benassi; Giorgia Bertazzoni; Eugenia Veratti; Daria Morini; Paola Azzoni; Maria P Costi; Alberto Venturelli; Silvia Pirondi; Stefania Seidenari; Cristina Magnoni
Journal:  Invest New Drugs       Date:  2011-09-01       Impact factor: 3.850

2.  Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells.

Authors:  P J Ferguson; J M DeMoor; M D Vincent; J Koropatnick
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

3.  Functional mechanism of the enhancement of 5-fluorouracil sensitivity by TUSC4 in colon cancer cells.

Authors:  Ming-Na Liu; Ai-Yun Liu; Feng-Hua Pei; Xiao Ma; Yu-Jing Fan; Ya-Ju DU; Bing-Rong Liu
Journal:  Oncol Lett       Date:  2015-10-13       Impact factor: 2.967

4.  Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment.

Authors:  P Schroeder; C Lindemann; K Dettmar; J Brieger; J Gosepath; B Pogorzelski; D Seimetz; J Atz
Journal:  Clin Transl Oncol       Date:  2011-12       Impact factor: 3.405

5.  Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase.

Authors:  Daniela Cardinale; Giambattista Guaitoli; Donatella Tondi; Rosaria Luciani; Stefan Henrich; Outi M H Salo-Ahen; Stefania Ferrari; Gaetano Marverti; Davide Guerrieri; Alessio Ligabue; Chiara Frassineti; Cecilia Pozzi; Stefano Mangani; Dimitrios Fessas; Remo Guerrini; Glauco Ponterini; Rebecca C Wade; M Paola Costi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-27       Impact factor: 11.205

6.  Discovery of safe and orally effective 4-aminoquinaldine analogues as apoptotic inducers with activity against experimental visceral leishmaniasis.

Authors:  Partha Palit; Abhijit Hazra; Arindam Maity; R S K Vijayan; Prabu Manoharan; Sukdeb Banerjee; Nirup B Mondal; Nanda Ghoshal; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

7.  Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features.

Authors:  H Was; J Czarnecka; A Kominek; K Barszcz; T Bernas; K Piwocka; B Kaminska
Journal:  Cancer Biol Ther       Date:  2017-12-22       Impact factor: 4.742

Review 8.  Relationship between head and neck cancer therapy and some genetic endpoints.

Authors:  Eliana Maria Minicucci; Glenda Nicioli da Silva; Daisy Maria Fávero Salvadori
Journal:  World J Clin Oncol       Date:  2014-05-10

9.  Resistance of a rodent malaria parasite to a thymidylate synthase inhibitor induces an apoptotic parasite death and imposes a huge cost of fitness.

Authors:  Francis W Muregi; Isao Ohta; Uchijima Masato; Hideto Kino; Akira Ishih
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

10.  Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine.

Authors:  Irene V Bijnsdorp; Reto A Schwendener; Herbert Schott; Iduna Fichtner; Kees Smid; Adrie C Laan; Sarah Schott; Nienke Losekoot; Richard J Honeywell; Godefridus J Peters
Journal:  Invest New Drugs       Date:  2009-12-03       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.